EntreChem SL, a biotechnology company that develops new biocatalytic processes, has published in Advanced Synthesis & Catalysis, the results of a collaborative research with Servier focused on enzymatic routes to improved syntheses of the heart-rate reducing drug Ivabradine. The key step involves a lipase-catalyzed kinetic resolution by alkoxycarbonylation of a racemic primary amine, or alternatively, the dynamic kinetic resolution by asymmetric bioamination of an aldehyde precursor catalyzed by a transaminase.
The results highlight the opportunities offered by enzymes for synthesis of chiral drugs. The transaminase-catalyzed bioamination is particularly powerful, since it enables a process that overcomes the yield hurdles of kinetic resolutions or crystallization approaches.
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
